Floatz logo

Sorafenib

Liver Cancer

First Affiliated Hospital Xi'an Jiaotong UniversitySmall moleculePhase 3Dormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
65/ 100

Competitive context

110 Active assets in the Liver Cancer cohort.

Asset / SponsorPhaseRating
Dexmedetomidine
Uppsala University Hospital
Phase 4BBB
Adriamycin
Shanghai Zhongshan Hospital
Phase 4BB
Xaliplatin
Sun Yat-sen University
Phase 3BB
Tranexamic Acid
Konkuk University Medical Center
Phase 4BB
Idarubicin
Second Affiliated Hospital of Guangzhou Medical University
Phase 3BB

View all 50 →

Same molecule, other indications

Sorafenib is also rated in:

renal cell carcinomaDormant
BBB
Indicative · Phase 4
79 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative · Phase 4
74 / 100
View asset →
adult hepatocellular carcinomaDormant
BBB
Indicative · Phase 3
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →